Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) first FDA approved treatment for Ebola virus
15 Ottobre 2020
The U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola
